Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$3.04 USD
+0.01 (0.33%)
Updated Jul 16, 2024 03:57 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACST 3.04 +0.01(0.33%)
Will ACST be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ACST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACST
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
ACST: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
TEVA to Pay $250 Million to Settle Price-Fixing Charges
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
Other News for ACST
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
Acasti Pharma achieves 50% enrollment in STRIVE-ON safety trial
Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)
ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024
What You Missed On Wall Street This Morning